1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Spinal Muscular Atrophy (SMA) Therapeutic Revenue
1.4 Market Analysis by Type
1.4.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Nusinersen
1.4.3 Onasemnogen Abeparvovec
1.5 Market by Application
1.5.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Application: 2021-2026
1.5.2 Nusinersen SMA
1.5.3 Onasemnogen Abeparvovec SMA
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Spinal Muscular Atrophy (SMA) Therapeutic Market
1.8.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Market Status and Outlook (2015-2026)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Production Capacity Market Share by Manufacturers (2015-2020)
2.2 Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share by Manufacturers (2015-2020)
2.3 Global Spinal Muscular Atrophy (SMA) Therapeutic Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Spinal Muscular Atrophy (SMA) Therapeutic Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume Market Share by Region (2015-2020)
3.2 Global Spinal Muscular Atrophy (SMA) Therapeutic Sales Revenue Market Share by Region (2015-2020)
3.3 North America Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume
3.3.1 North America Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume Growth Rate (2015-2020)
3.3.2 North America Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.4 East Asia Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume
3.4.1 East Asia Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume Growth Rate (2015-2020)
3.4.2 East Asia Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.5 Europe Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume (2015-2020)
3.5.1 Europe Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume Growth Rate (2015-2020)
3.5.2 Europe Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.6 South Asia Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume (2015-2020)
3.6.1 South Asia Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume Growth Rate (2015-2020)
3.6.2 South Asia Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.7 Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume (2015-2020)
3.7.1 Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume Growth Rate (2015-2020)
3.7.2 Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.8 Middle East Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume (2015-2020)
3.8.1 Middle East Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume Growth Rate (2015-2020)
3.8.2 Middle East Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.9 Africa Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume (2015-2020)
3.9.1 Africa Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume Growth Rate (2015-2020)
3.9.2 Africa Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.10 Oceania Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume (2015-2020)
3.10.1 Oceania Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume Growth Rate (2015-2020)
3.10.2 Oceania Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.11 South America Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume (2015-2020)
3.11.1 South America Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume Growth Rate (2015-2020)
3.11.2 South America Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.12 Rest of the World Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume (2015-2020)
3.12.1 Rest of the World Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume Growth Rate (2015-2020)
3.12.2 Rest of the World Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
4 North America
4.1 North America Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume Market Share by Type (2015-2020)
14.2 Global Spinal Muscular Atrophy (SMA) Therapeutic Sales Revenue Market Share by Type (2015-2020)
14.3 Global Spinal Muscular Atrophy (SMA) Therapeutic Sales Price by Type (2015-2020)
15 Consumption Analysis by Application
15.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Consumption Volume by Application (2015-2020)
15.2 Global Spinal Muscular Atrophy (SMA) Therapeutic Consumption Value by Application (2015-2020)
16 Company Profiles and Key Figures in Spinal Muscular Atrophy (SMA) Therapeutic Business
16.1 Biogen
16.1.1 Biogen Company Profile
16.1.2 Biogen Spinal Muscular Atrophy (SMA) Therapeutic Product Specification
16.1.3 Biogen Spinal Muscular Atrophy (SMA) Therapeutic Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.2 Astellas Pharma
16.2.1 Astellas Pharma Company Profile
16.2.2 Astellas Pharma Spinal Muscular Atrophy (SMA) Therapeutic Product Specification
16.2.3 Astellas Pharma Spinal Muscular Atrophy (SMA) Therapeutic Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.3 Novartis
16.3.1 Novartis Company Profile
16.3.2 Novartis Spinal Muscular Atrophy (SMA) Therapeutic Product Specification
16.3.3 Novartis Spinal Muscular Atrophy (SMA) Therapeutic Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.4 Roche
16.4.1 Roche Company Profile
16.4.2 Roche Spinal Muscular Atrophy (SMA) Therapeutic Product Specification
16.4.3 Roche Spinal Muscular Atrophy (SMA) Therapeutic Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.5 Genzyme Corporation
16.5.1 Genzyme Corporation Company Profile
16.5.2 Genzyme Corporation Spinal Muscular Atrophy (SMA) Therapeutic Product Specification
16.5.3 Genzyme Corporation Spinal Muscular Atrophy (SMA) Therapeutic Production Capacity, Revenue, Price and Gross Margin (2015-2020)
17 Spinal Muscular Atrophy (SMA) Therapeutic Manufacturing Cost Analysis
17.1 Spinal Muscular Atrophy (SMA) Therapeutic Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Spinal Muscular Atrophy (SMA) Therapeutic
17.4 Spinal Muscular Atrophy (SMA) Therapeutic Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Spinal Muscular Atrophy (SMA) Therapeutic Distributors List
18.3 Spinal Muscular Atrophy (SMA) Therapeutic Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Spinal Muscular Atrophy (SMA) Therapeutic (2021-2026)
20.2 Global Forecasted Revenue of Spinal Muscular Atrophy (SMA) Therapeutic (2021-2026)
20.3 Global Forecasted Price of Spinal Muscular Atrophy (SMA) Therapeutic (2015-2026)
20.4 Global Forecasted Production of Spinal Muscular Atrophy (SMA) Therapeutic by Region (2021-2026)
20.4.1 North America Spinal Muscular Atrophy (SMA) Therapeutic Production, Revenue Forecast (2021-2026)
20.4.2 East Asia Spinal Muscular Atrophy (SMA) Therapeutic Production, Revenue Forecast (2021-2026)
20.4.3 Europe Spinal Muscular Atrophy (SMA) Therapeutic Production, Revenue Forecast (2021-2026)
20.4.4 South Asia Spinal Muscular Atrophy (SMA) Therapeutic Production, Revenue Forecast (2021-2026)
20.4.5 Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Production, Revenue Forecast (2021-2026)
20.4.6 Middle East Spinal Muscular Atrophy (SMA) Therapeutic Production, Revenue Forecast (2021-2026)
20.4.7 Africa Spinal Muscular Atrophy (SMA) Therapeutic Production, Revenue Forecast (2021-2026)
20.4.8 Oceania Spinal Muscular Atrophy (SMA) Therapeutic Production, Revenue Forecast (2021-2026)
20.4.9 South America Spinal Muscular Atrophy (SMA) Therapeutic Production, Revenue Forecast (2021-2026)
20.4.10 Rest of the World Spinal Muscular Atrophy (SMA) Therapeutic Production, Revenue Forecast (2021-2026)
20.5 Forecast by Type and by Application (2021-2026)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2021-2026)
20.5.2 Global Forecasted Consumption of Spinal Muscular Atrophy (SMA) Therapeutic by Application (2021-2026)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Spinal Muscular Atrophy (SMA) Therapeutic by Country
21.2 East Asia Market Forecasted Consumption of Spinal Muscular Atrophy (SMA) Therapeutic by Country
21.3 Europe Market Forecasted Consumption of Spinal Muscular Atrophy (SMA) Therapeutic by Countriy
21.4 South Asia Forecasted Consumption of Spinal Muscular Atrophy (SMA) Therapeutic by Country
21.5 Southeast Asia Forecasted Consumption of Spinal Muscular Atrophy (SMA) Therapeutic by Country
21.6 Middle East Forecasted Consumption of Spinal Muscular Atrophy (SMA) Therapeutic by Country
21.7 Africa Forecasted Consumption of Spinal Muscular Atrophy (SMA) Therapeutic by Country
21.8 Oceania Forecasted Consumption of Spinal Muscular Atrophy (SMA) Therapeutic by Country
21.9 South America Forecasted Consumption of Spinal Muscular Atrophy (SMA) Therapeutic by Country
21.10 Rest of the world Forecasted Consumption of Spinal Muscular Atrophy (SMA) Therapeutic by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer